ConductScience.org, home

Paper503223

Induction and kinetics of natural killer cells in humans following interferon therapy.

Huddlestone JR and 2 others. Nature, 1979. Cited by 156 papers, by iCite.

Cite this record

ConductScience Library. Induction and kinetics of natural killer cells in humans following interferon therapy. Papers, record 503223. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/503223

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Induction and kinetics of natural killer cells in humans following interferon therapy.
PubMed
Journal
Nature
PubMed
Year
1979
PubMed
Publication types
Journal Article, Research Support, U.S. Gov't, P.H.S.
PubMed
Citations, by iCite
156
iCite
Relative citation ratio, by iCite
4.61
iCite
Revised in PubMed
2019-06-17
PubMed

Authors3

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Huddlestone JRJ R
2Merigan TC JrT C
3Oldstone MBM B

Source PubMed

Download CSV of authors

Topics6

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Immunity, CellularMajor topic
Immunity, InnateMajor topic
InterferonsMajor topic
Killer Cells, NaturalMajor topic
Humans
Lymphoma

Cited by34

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 156 citations.

PMIDTitleJournalYearIn PapersSource
41107895The role of NK cells in regulating tumorimmunity: current state, challenges and future strategies.Cancer Cell Int2025https://conductscience.org/library/papers/41107895PubMed
31547251NK Cell Hyporesponsiveness: More Is Not Always Better.Int J Mol Sci2019https://conductscience.org/library/papers/31547251PubMed
27010978A Computational Model of Inhibition of HIV-1 by Interferon-Alpha.PLoS One2016https://conductscience.org/library/papers/27010978PubMed
25469725Controlled infection with a therapeutic virus defines the activation kinetics of human natural killer cells in vivo.Clin Exp Immunol2015https://conductscience.org/library/papers/25469725PubMed
24941370Natural killer activity: early days, advances, and seminal observations.Crit Rev Oncog2014https://conductscience.org/library/papers/24941370PubMed
6690072Phase-I trial of UltrapureTM human leukocyte interferon in human malignancy.Cancer Chemother Pharmacol1984https://conductscience.org/library/papers/6690072PubMed
6466539Therapy with high dose recombinant alpha 2 interferon (IFN-alpha 2) produces a depression in natural killer cell cytotoxicity.Br J Cancer1984https://conductscience.org/library/papers/6466539PubMed
6379511Clinical effect of interferon in malignant brain tumours.Neurosurg Rev1984https://conductscience.org/library/papers/6379511PubMed
6292259The biology of the human natural killer cell.J Clin Immunol1982https://conductscience.org/library/papers/6292259PubMed
6284642Natural cell-mediated cytotoxicity of bovine mononuclear cells against virus-infected cells.Infect Immun1982https://conductscience.org/library/papers/6284642PubMed
6251708Antibody-mediated destruction of virus-infected cells.Adv Immunol1980https://conductscience.org/library/papers/6251708PubMed
6237664In vitro modulation of human natural killer cell activity by interferon: generation of adherent suppressor cells.Br J Cancer1984https://conductscience.org/library/papers/6237664PubMed
6203638Natural killer cells in human solid tumors.Cancer Metastasis Rev1983https://conductscience.org/library/papers/6203638PubMed
6180219Effect of human fibroblast interferon on natural killer cell activity: stimulation in vitro and inhibition in vivo.Klin Wochenschr1982https://conductscience.org/library/papers/6180219PubMed
6178542Insensitivity to interferon of NK cells from patients with systemic lupus erythematosus.Clin Exp Immunol1982https://conductscience.org/library/papers/6178542PubMed
6178525Clinical and immunological studies of human fibroblast interferon.Cancer Chemother Pharmacol1982https://conductscience.org/library/papers/6178525PubMed
6177714Medullasin enhances human natural killer cell activity.J Clin Invest1982https://conductscience.org/library/papers/6177714PubMed
6175462Natural killing of cytomegalovirus-infected fibroblasts by human mononuclear leucocytes.Clin Exp Immunol1981https://conductscience.org/library/papers/6175462PubMed
6174541Augmentation of natural killer (NK) cell activity by a streptococcal preparation, OK-432, in patients with malignant tumors.J Clin Immunol1981https://conductscience.org/library/papers/6174541PubMed
6173188Interferons and interferon inducers: development of clinical usefulness and therapeutic promise.Drugs1982https://conductscience.org/library/papers/6173188PubMed

See all 34 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/503223

GET https://conductscience.org/api/papers/v1/503223/cited_by?page=2